Estrella Immunopharma Inc. (ESLA) - Total Liabilities
Based on the latest financial reports, Estrella Immunopharma Inc. (ESLA) has total liabilities worth $13.54 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Estrella Immunopharma Inc. to assess how effectively this company generates cash.
Estrella Immunopharma Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Estrella Immunopharma Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Estrella Immunopharma Inc. (ESLA) shareholders funds for net asset value and shareholders' equity analysis.
Estrella Immunopharma Inc. Competitors by Total Liabilities
The table below lists competitors of Estrella Immunopharma Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
Korea | ₩160.29 Billion |
|
Skarbiec Holding S.A.
WAR:SKH
|
Poland | zł740.92 Million |
|
JC Chemical Co. Ltd
KQ:137950
|
Korea | ₩214.58 Billion |
|
Surf Air Mobility Inc.
NYSE:SRFM
|
USA | $199.34 Million |
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
Turkey | TL1.27 Billion |
|
MCT Bhd
KLSE:5182
|
Malaysia | RM550.59 Million |
|
Ferrum S.A.
BA:FERR
|
Argentina | AR$69.89 Billion |
|
Applied BioCode
TW:6598
|
Taiwan | NT$343.23 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Estrella Immunopharma Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Estrella Immunopharma Inc. (ESLA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Estrella Immunopharma Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Estrella Immunopharma Inc. (2020–2025)
The table below shows the annual total liabilities of Estrella Immunopharma Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $13.54 Million | +351.88% |
| 2024-12-31 | $3.00 Million | +1558.57% |
| 2023-12-31 | $180.70K | -93.80% |
| 2022-12-31 | $2.92 Million | -51.09% |
| 2021-12-31 | $5.96 Million | -- |
| 2020-12-31 | $0.00 | -- |
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leuke… Read more